Helen Rizos

11.8k citations

142 papers · 6.5k indexed · 2 hit papers · h-index 46

Impact in

Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Cancer-related Molecular Pathways
Cancer Research top 1%
- Cancer Genomics and Diagnostics

Papers in

Oncology 92
- Cancer Immunotherapy and Biomarkers 31
- Cutaneous Melanoma Detection and Management 25
- CAR-T cell therapy research 23
- Cancer-related Molecular Pathways 21
Cancer Research 27
- Cancer Genomics and Diagnostics 21

Co-authors: Richard Kefford Georgina V. Long Richard A. Scolyer Matteo S. Carlino Alexander M. Menzies Jenny Lee Therese M. Becker Su Yin Lim
Journals: Journal of Clinical Oncology (14 papers)Clinical Cancer Research (8 papers)Journal of Investigative Dermatology (8 papers)Pigment Cell & Melanoma Research (7 papers)Annals of Oncology (7 papers)
Partner nations: Australia United States United Kingdom

In The Last Decade

Helen Rizos

138 papers receiving 6.4k citations

Hit Papers

align trajectories log scale

A scoping review of factors influencing the implementation of liquid biopsy for cancer care 2025 · 16 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2025 Journal of Experimental & Clinical Cancer Research
2014 Clinical Cancer Research

Peers

Countries citing papers authored by Helen Rizos

Since Specialization

Citations

This map shows the geographic impact of Helen Rizos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helen Rizos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helen Rizos more than expected).

Fields of papers citing papers by Helen Rizos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helen Rizos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helen Rizos. The network helps show where Helen Rizos may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Helen Rizos, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Helen Rizos Line = papers co-authored together Helen Rizos links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Circulating IFNγ-associated protein signatures predict response to neoadjuvant immunotherapy in patients with stage III melanoma Cancer Cell International ·Fengtang Yang, Su Yin Lim, Inês Pires da Silva, Lijia Yu, 裕之太田, Alexander M Menzies, Georgina V. Long, Jean Yang, Helen Rizos	2025	0
2	Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma Annals of Oncology ·Alexander M. Menzies, Serigne Lo, Robyn P.M. Saw, Maria Gonzalez, Sydney Ch’ng, Pablo Mori Bregante, Kerwin F. Shannon, Kei Yoneda, Jenny Lee, Louise Emmett, Tara Kheradyar, Shahboz Khujamov, Jonathan R. Stretch, John F. Thompson, Eduardo Rivé Lockwood, Helen Rizos, Raquel Pereira Buroxid, Georgina V. Long	2024	8
3	PKC-independent PI3K signalling diminishes PKC inhibitor sensitivity in uveal melanoma Oncogenesis ·John Park, H.K. Pan, Ashleigh Stewart, Matteo S. Carlino, Su Yin Lim, Helen Rizos	2024	4
4	Checkpoint kinase 1 inhibitor + low‐dose hydroxyurea efficiently kills BRAF inhibitor‐ and immune checkpoint inhibitor‐resistant melanomas Pigment Cell & Melanoma Research ·Zhen Zeng, Dennis H. Mcpherson, A. Alavi, Helen Rizos, Riccardo Dolcetti, Jazmina L. Gonzalez Cruz, James W. Wells, Brian Gabrielli	2023	2
5	The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma Nature Communications ·Su Yin Lim, Elena Shklovskaya, Jenny Lee, Bernadette Pedersen, Ashleigh Stewart, M Masumori, Mal Irvine, Brindha Shivalingam, Robyn P.M. Saw, Alexander M. Menzies, Matteo S. Carlino, Richard A. Scolyer, Georgina V. Long, Helen Rizos	2023	67
6	Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA Frontiers in Oncology ·Russell J. Diefenbach, Jenny Lee, Ashleigh Stewart, Alexander M. Menzies, Matteo S. Carlino, Robyn P.M. Saw, Jonathan R. Stretch, Georgina V. Long, Richard A. Scolyer, Helen Rizos	2022	1
7	Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma Journal of Investigative Dermatology ·Farzana Ahmed, Hsin‐Yi Tseng, Antonio Ahn, Dilini Gunatilake, Sara Alavi, Michael R. Eccles, Helen Rizos, Stuart Gallagher, Jessamy Tiffen, Peter Hersey, Abdullah Al Emran	2021	16
8	Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors Clinical Cancer Research ·Jenny Lee, Alexander M. Menzies, Matteo S. Carlino, Ashleigh C. McEvoy, Shahneen Sandhu, Alison M. Weppler, Russell J. Diefenbach, Sarah‐Jane Dawson, Richard Kefford, Michael Millward, Diana Mirey, Yongbiao Yu, Elin S. Gray, Stephen Q. Wong, Richard A. Scolyer, Georgina V. Long, Helen Rizos	2020	62
9	Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition Nature Communications ·Jenny Lee, Elena Shklovskaya, Su Yin Lim, Matteo S. Carlino, Alexander M. Menzies, Ashleigh Stewart, Bernadette Pedersen, flowstef, Sara Alavi, Jean Yang, Dario Strbenac, Robyn P.M. Saw, John F. Thompson, James S. Wilmott, Richard A. Scolyer, Georgina V. Long, Richard Kefford, Helen Rizos	2020	193
10	Co‐targeting bromodomain and extra‐terminal proteins and MCL1 induces synergistic cell death in melanoma International Journal of Cancer ·Hsin‐Yi Tseng, Д.П. Чекулаев, Abdullah Al Emran, Dilini Gunatilake, G Posteraro, Carleen Cullinane, Ken Dutton‐Regester, Helen Rizos, Nicholas K. Hayward, Grant A. McArthur, Peter Hersey, Jessamy Tiffen, Stuart Gallagher	2020	20
11	Charge Conversional Biomimetic Nanocomplexes as a Multifunctional Platform for Boosting Orthotopic Glioblastoma RNAi Therapy Nano Letters ·Yanjie Liu, Yan Zou, Chan Feng, Albert Lee, Jinlong Yin, Roger S. Chung, Salvador Domínguez, Helen Rizos, Wei Tao, Meng Zheng, Omid C. Farokhzad, Bingyang Shi	2020	145
12	Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF -Mutant Melanoma Clinical Cancer Research ·Inês Pires da Silva, Kevin Wang, James S. Wilmott, Jeff Holst, Matteo S. Carlino, John Park, Camelia Quek, Matthew Wongchenko, Yibing Yan, Graham J. Mann, Douglas B. Johnson, Jennifer L. McQuade, Rajat Rai, Richard Kefford, Helen Rizos, Richard A. Scolyer, Jean Yang, Georgina V. Long, Alexander M. Menzies	2019	48
13	Somatic Hypermutation of the YAP Oncogene in a Human Cutaneous Melanoma Molecular Cancer Research ·Xiaomeng Zhang, Jian Tang, Ismael A. Vergara, Youfang Zhang, Louise Marie Roth, Luciana Quintana, Christopher Mintoff, Andrew J. Colebatch, Lachlan McIntosh, Francisca Elías-Bezares, Himani Himani, Helen Rizos, Georgina V. Long, Nicholas K. Hayward, Grant A. McArthur, Anthony T. Papenfuss, Kieran F. Harvey, Mark Shackleton	2019	29
14	Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy Clinical Cancer Research ·Su Yin Lim, Jenny Lee, Tuba N. Gide, Alexander M. Menzies, Alexander Guminski, Matteo S. Carlino, Edmond J. Breen, Jean Yang, Shila Ghazanfar, Richard Kefford, Richard A. Scolyer, Georgina V. Long, Helen Rizos	2018	271
15	PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors Clinical Cancer Research ·Hojabr Kakavand, Robert V. Rawson, Gulietta M. Pupo, Jean Yang, Alexander M. Menzies, Matteo S. Carlino, Richard Kefford, Julie R. Howle, Robyn P.M. Saw, John F. Thompson, James S. Wilmott, Georgina V. Long, Richard A. Scolyer, Helen Rizos	2017	63
16	Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1α and Oxidative Phosphorylation in Melanoma Cancer Research ·Y.N. Vashisht Gopal, Helen Rizos, Guo Chen, Wanleng Deng, Dennie T. Frederick, Zachary A. Cooper, Richard A. Scolyer, Gulietta M. Pupo, Kakajan Komurov, Vasudha Sehgal, Jiexin Zhang, Lalit R. Patel, Cristiano Gonçalves Pereira, Bradley M. Broom, Gordon B. Mills, Prahlad T. Ram, Paul D. Smith, Jennifer A. Wargo, Georgina V. Long, Michael A. Davies	2014	148
17	Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients Clinical Cancer Research ·Matteo S. Carlino, Carina Fung, Hamideh Shahheydari, Jason R. Todd, Suzanah C. Boyd, Mal Irvine, Adnan Nagrial, Richard A. Scolyer, Richard Kefford, Georgina V. Long, Helen Rizos	2014	53
18	BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact Clinical Cancer Research ·Helen Rizos, Alexander M. Menzies, Gulietta M. Pupo, Matteo S. Carlino, Carina Fung, Jessica Hyman, Lauren E. Haydu, Branka Mijatov, Therese M. Becker, Suzanah C. Boyd, Julie R. Howle, Robyn P.M. Saw, John F. Thompson, Richard Kefford, Richard A. Scolyer, Georgina V. Long Hit paper breakdown →	2014	382
19	Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma Molecular Oncology ·Matteo S. Carlino, Jason R. Todd, Kavitha Gowrishankar, Branka Mijatov, Gulietta M. Pupo, Carina Fung, 우종범, Peter Hersey, Georgina V. Long, Richard Kefford, Helen Rizos	2014	90
20	Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma Molecular Cancer Therapeutics ·Matteo S. Carlino, Kavitha Gowrishankar, Catherine A.B. Saunders, Gulietta M. Pupo, 우종범, Xu Dong Zhang, Robyn P.M. Saw, Therese M. Becker, Richard Kefford, Georgina V. Long, Helen Rizos	2013	61

About Helen Rizos

Helen Rizos is a scholar working on Oncology, Cancer Research, Molecular Biology, Immunology and Immunology and Allergy, having authored 142 papers that have together received 6.5k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (57 papers), Cancer Immunotherapy and Biomarkers (31 papers), Cutaneous Melanoma Detection and Management (25 papers), CAR-T cell therapy research (23 papers), Immunotherapy and Immune Responses (21 papers), Cancer Genomics and Diagnostics (21 papers), Cancer-related Molecular Pathways (21 papers) and Ubiquitin and proteasome pathways (8 papers). The work is most often cited by research in Oncology (3.5k citations), Cancer Research (1.4k citations), Immunology (1.3k citations), Molecular Biology (4.1k citations) and Cell Biology (514 citations). Helen Rizos has collaborated with scholars based in Australia, United States and United Kingdom. Frequent co-authors include Richard Kefford, Georgina V. Long, Richard A. Scolyer, Matteo S. Carlino, Alexander M. Menzies, Jenny Lee, Therese M. Becker, Su Yin Lim, Graham J. Mann and Gulietta M. Pupo. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Journal of Investigative Dermatology, Pigment Cell & Melanoma Research and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact